A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Malignant Neoplasm
Interventions: DRUG: NPX267
Sponsor: NextPoint Therapeutics, Inc.